(1 - 10 von 10
)
Verleihungen - Artikel Deutsches Ärzteblatt
www.aerzteblatt.de
Dr. rer. nat. Sven Hammerschmidt, München. Den Promotionspreis in Höhe von 500 Euro erhielt Dr. Sven Hobbie, Zürich. EB. › app › print
16 Teilnehmer absolvieren Truppmannausbildung bei der ...
www.nwzonline.de
— ... Sven Hobbie und Tim Hobbie von der Ortswehr Schweewarden, Leon Körnig von der Ortswehr Einswarden, Thore Minßen, Thies Minßen, ... › plus-wesermarsch › nordenha...
15 Swiss startups to present at Swiss Biotech Day
www.startupticker.ch
Juvabis GmbH, Sven Hobbie (CEO) – designs next-generation aminoglycoside antibiotics that withstand mechanisms of bacterial ...
84th Edition – November | IMI Innovative Medicines Initiative
www.imi.europa.eu
systemic infections in humans,' says Sven Hobbie, who leads the programme.
Continuing Education—2022 SOT Annual Meeting
www.toxicology.org
How to Select the Best Candidate with Minimal Ototoxicity. Sven Hobbie, Universität Zürich, Zurich, Switzerland. Sunday, 1:15 PM to 5:00 PM ... › events
News - Juvabis
www.juvabis.ch
Interview with Founding CEO Dr Sven Hobbie as part of Antimicrobial Resistance campaign, World Antimicrobial Awareness Week, › news
16:00 T1: Using the Ensembl REST APIs to programmatically ...
www.professionalabstracts.com
— Sven Hobbie (Juvabis AG, Switzerland). Joint Session, Montreal. 15: :30. EMBO & [BC]2 Flash talks. Chair: Sven Bergmann (University of ... › programm...
Juvabis causes a stir with new antibiotic - Startupticker.ch
www.startupticker.ch
— ... and clearly support our commitment to progressing the clinical development of EBL-1003,” said Dr. Sven Hobbie, CEO of Juvabis. › news
Pitch Night 2019: The Future of HealthTech
bostonstartupsguide.com
— Juvabis AG | Sven Hobbie | ETH Zurich. Drug-resistant bacteria are a threat to modern medicine. Juvabis, a joint startup of the ETH and ... › p...
sortiert nach Relevanz / Datum